<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00254735</url>
  </required_header>
  <id_info>
    <org_study_id>5077/9059</org_study_id>
    <secondary_id>D1441C09059</secondary_id>
    <nct_id>NCT00254735</nct_id>
  </id_info>
  <brief_title>Quetiapine Augmentation in Severe Obsessive Compulsive Disorder</brief_title>
  <official_title>Quetiapine Augmentation in Severe Obsessive Compulsive Disorder (OCD) - Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy of quetiapine or placebo added to
      baseline treatment of SSRI/clomipramine for the treatment of OCD in adult subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2002</start_date>
  <completion_date type="Actual">March 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute change of OCD symptoms from baseline to endpoint on the total Y-BOCS score.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of comorbid psychiatric symptoms and measures of quality of life from baseline to endpoint documented by different scales.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the safety and tolerability profile of quetiapine compared to placebo added to a baseline medication of SSRI/clomipramine.</measure>
  </secondary_outcome>
  <enrollment type="Actual">44</enrollment>
  <condition>Obsessive Compulsive Disorder</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>quetiapine fumarate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SSRI/Clomipramine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent, men and women aged ³18 to £65 years with diagnosis of OCD, at
             least 12 weeks of treatment with SSRI or clomipramine

        Exclusion Criteria:

          -  Substance abuse or dependence, female patients who are pregnant, lactating or at risk
             of pregnancy, known intolerance or lack of response to quetiapine, use of
             antihypertensive medication with changing doses
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AstraZeneca Germany Medical Director, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lübeck</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2005</study_first_submitted>
  <study_first_submitted_qc>November 15, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2005</study_first_posted>
  <last_update_submitted>December 14, 2007</last_update_submitted>
  <last_update_submitted_qc>December 14, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2007</last_update_posted>
  <keyword>Obsessive Compulsive Disorder (OCD)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Compulsive Personality Disorder</mesh_term>
    <mesh_term>Obsessive-Compulsive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Quetiapine Fumarate</mesh_term>
    <mesh_term>Clomipramine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

